Regional Cancer Care Associates

CLIA Laboratory Citation Details

2
Total Citations
18
Total Deficiencyies
9
Unique D-Tags
CMS Certification Number 31D0677457
Address 326 Professional View Drive, Freehold, NJ, 07728
City Freehold
State NJ
Zip Code07728
Phone732 677-5236
Lab DirectorJEFFREY SILBERBERG

Citation History (2 surveys)

Survey - December 19, 2025

Survey Type: Special

Survey Event ID: 90EO11

Deficiency Tags: D2016 D6000 D0000 D2130 D6016

Summary:

Summary Statement of Deficiencies D0000 A proficiency testing desk review survey was performed on December 19, 2025, the laboratory was found not in compliance with the following CONDITION LEVEL DEFICIENCIES D2016 - 42 C.F.R. 493.803 Condition: Successful participation [proficiency testing] D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on an office review of the CASPER reports 153 and 155 and proficiency testing provider reports, the laboratory failed to achieve 80% or more in two out of three events for the analytes Red Cell Distribution Width (RDW), Neutrophils/Granulocytes Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- % (NEU/GRAN %), Neutrophils/Granulocytes Absolute (NEU/GRAN Absolute), Eosinophils (EOS), Eosinophils Absolute (EOS Absolute), Basophils % (BASO %), Basophils Absolute (BASO Absolute) with the College Of American Pathologists (CAP). Cross refer to D2130. D2130 HEMATOLOGY CFR(s): 493.851(f) (f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CASPER 155 report and graded results from College Of American Pathologists (CAP). The laboratory failed to achieve satisfactory performance (80% or greater) for two constitutive proficiency testing (PT) events in the subspecialty Hematology for the analytes Red Cell Distribution Width (RDW), Neutrophils/Granulocytes % (NEU/GRAN %), Neutrophils/Granulocytes Absolute (NEU/GRAN Absolute), Eosinophils % (EOS %), Eosinophils Absolute (EOS Absolute), Basophils % (BASO %), Basophils Absolute (BASO Absolute) resulting in initial unsuccessful performance. The findings include: 1) A review of the CASPER 155 report revealed the following. a) The laboratory scored 0% for RDW in event 2- 2025. b) The laboratory scored 0% for NEU/GRAN % in event 2-2025. c) The laboratory scored 0% for NEU/GRAN Absolute in event 2-2025. d) The laboratory scored 0% for ESO % in event 2-2025. e) The laboratory scored 0% for ESO Absolute in event 2-2025. f) The laboratory scored 0% for BASO % in event 2-2025. g) The laboratory scored 0% for BASO Absolute in event 2-2025. h) The laboratory scored 0% for RDW in event 3-2025. i) The laboratory scored 0% for NEU/GRAN % in event 3-2025. j) The laboratory scored 0% for NEU/GRAN Absolute in event 3-2025. k) The laboratory scored 0% for ESO % in event 3-2025. l) The laboratory scored 0% for ESO Absolute in event 3-2025. m) The laboratory scored 0% for BASO % in event 3-2025. n) The laboratory scored 0% for BASO Absolute in event 3-2025. 2. A review of CAP graded results confirmed the laboratory failed two consecutive Proficiency Testing (PT) events. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on review of the CASPER 155 report and graded results from the College of American Pathologists (CAP). The Laboratory Director (LD) failed to provide overall management and direction to laboratory personnel to ensure that the Proficiency Testing (PT) surveys are performed satisfactorily and in compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations. The findings include: 1. The LD failed to ensure PT surveys are performed satisfactorily and in compliance with CLIA regulations. Cross refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES -- 2 of 3 -- CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a review of the CASPER 155 report and graded results from the College of American Pathologists (CAP), the Laboratory Director (LD) failed to ensure successful participation in a Department of Health and Human Services (DHHS) approved Proficiency Testing (PT) program for two consecutive PT events for the analytes Red Cell Distribution Width (RDW), Neutrophils/Granulocytes % (NEU /GRAN %), Neutrophils/Granulocytes Absolute (NEU/GRAN Absolute), Eosinophils (EOS), Eosinophils Absolute (EOS Absolute), Basophils % (BASO %), Basophils Absolute (BASO Absolute) , resulting in initial unsuccessful performance. Cross refer to D2130. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 27, 2025

Survey Type: Standard

Survey Event ID: 15J711

Deficiency Tags: D3031 D6000 D6016 D6000 D6020 D6023 D2016 D3031 D6019 D6016 D6019 D6020 D6023

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on surveyor review of the Proficiency Testing (PT) evaluation records, work records and interview with Technical Consultant (TC) the laboratory failed to participate in PT Hematology event FH2-C-2024 with the College of American Pathologists (CAP) from 11/6/24 to 1/27/25. The findings include: 1. The laboratory failed to participate in PT Hematology event FH2-C-2024. 2. The laboratory did not take

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access